Fig. 4
From: RRP9 promotes gemcitabine resistance in pancreatic cancer via activating AKT signaling pathway
RRP9 overexpression induces gemcitabine resistance in PC in vivo. A Representative images showing tumor masses removed from mice with xenografted tumors formed by RRP9-overexpressing or RRP9-silenced cells after gemcitabine treatment. B Luminescence signal of xenografted tumors formed by RRP9-overexpressing or RRP9-silenced PC cells in mice after exposure to gemcitabine. C Tumor volumes were calculated on timing that indicated. Data are denoted by mean ± SD, n = 5. D Tumor weights of the xenografted tumors formed by RRP9-overexpressing or RRP9-silenced cells after gemcitabine treatment. Data are presented as mean ± SD, n = 5. E Representative images of RRP9 (scale bar: 50 μm) and TUNEL immunofluorescence staining (scale bar: 100 μm) in xenografted tumors formed by RRP9-overexpressing or RRP9-silenced cells after gemcitabine treatment. Quantification of apoptotic data. Data are denoted by mean ± SD, n = 3. Note: *p < 0.05, **p < 0.01